Article: Other News To Note.

o Amylin Pharmaceuticals Inc., of San Diego, said initial purchasers in its recent private placement of $150 million of 2.25 percent convertible senior notes due in 2008 elected to exercise their option to purchase another $25 million in principal amount of the notes. The closing for the additional $25 million purchase is expected Tuesday. Amylin intends to use the proceeds for research and development, the planned commercialization of its diabetes product, Symlin, pending regulatory approvals, and general corporate purposes, it said. (See BioWorld Today, June 18, 2003.)

o Antisoma plc, of London, said it would complete its pivotal Phase III SMART study of R1549 ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!